News
GSK files Blenrep in EU, seeking return to market

GSK files Blenrep in EU, seeking return to market

Less than two years after pulling multiple myeloma therapy Blenrep off most markets around the world, GSK has filed for approval of the drug in the EU once again, hoping to restore its bloc

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

News
MSD hits a hurdle with its LAG-3 programme

MSD hits a hurdle with its LAG-3 programme

MSD's combination of PD-1 inhibitor Keytruda and experimental LAG-3 inhibitor favezelimab has failed a phase 3 trial in patients with previously treated PD-L1-positive microsatellite stable

Patients

R&D

Partner Content

R&D
FT Global Pharma & Biotech Summit 2024 banner
Partner Content

FT Global Pharma & Biotech Summit 2024

The Global Pharma and Biotech Summit is the essential annual event for you to stay on top of the latest trends and innovations in life sciences.

R&D
9th CDD For Biologics Summit 2024 banner
Partner Content

9th CDD For Biologics Summit 2024

Integrate Computational Biology, Generative AI & Machine Learning to Revolutionize Biologics Drug Discovery & Development